Jasper Therapeutics
Quarterly Financials
| Values in thousands | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
Gross Profit | -21 | -290 | -258 | |
EBITDA | -1,153 | -8,811 | -18,507 | -26,465 |
EBIT | -1,174 | -9,101 | -18,736 | -26,723 |
Net Income | -1,174 | -9,101 | -18,736 | -26,723 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Free Cash Flow | -14,548 | -21,867 | -16,999 | -15,460 |
Cash | 14,144 | 28,692 | 50,899 | 39,510 |
Basic Shares | 15,333 | 15,333 | 16,635 | 15,333 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $13,511 |
Gross Profit | -1,056 | -1,373 | -1,108 | -1,310 |
EBITDA | -74,745 | -69,896 | -63,357 | -36,710 |
EBIT | -75,801 | -71,269 | -64,465 | -37,685 |
Net Income | -75,801 | -71,269 | -64,465 | -37,685 |
Net Change In Cash | 0 | 0 | 0 | 13,511 |
Cost of Revenue | -46,379 | |||
Free Cash Flow | -77,168 | -63,154 | -52,334 | -46,434 |
Cash | 28,692 | 71,637 | 86,887 | 38,250 |
Basic Shares | 15,333 | 14,584 | 10,439 | 3,648 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-03-31 | -$0.38 |
2025-12-31 | -$0.54 |
2025-09-30 | -$1.25 |
2025-06-30 | -$1.74 |